Well Referenced

Tag: COVID-19

Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial”

This corrigendum, published in 2022, addresses corrections to the original 2021 pilot study that evaluated intravenous ozonized saline as an adjunctive treatment for moderate COVID-19 cases. While the specific corrections are not detailed in the available abstract, such corrigenda typically involve amendments to data, authorship, or methodological details. The original

Read More »
June 26, 2025 No Comments

The great Texas COVID tragedy

This 2022 commentary by Peter J. Hotez in PLOS Global Public Health examines the disproportionate impact of COVID-19 in Texas. Despite the availability of vaccines by May 1, 2021, approximately 40,000 of the 90,000 COVID-19 deaths in Texas occurred after this date, with 85% of the 2021 deaths among the

Read More »
June 26, 2025 No Comments

Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations

This 2021 review article explores the potential of methylene blue (MB) as a therapeutic agent for COVID-19, focusing on its mechanisms of action and clinical investigations. MB exhibits multiple antiviral and immunomodulatory properties: it can inhibit SARS-CoV-2 replication by interfering with the viral spike protein’s binding to ACE2 receptors, disrupt

Read More »
June 26, 2025 No Comments

Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2

This Phase 2 randomized, controlled, open-label clinical trial evaluated the efficacy of oral methylene blue (MB) in hospitalized patients with severe COVID-19. Eighty patients were randomized to receive either MB plus standard of care (SOC) or SOC alone. The MB group showed significant improvements in oxygen saturation (SpO₂) and respiratory

Read More »
June 26, 2025 No Comments

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

This Canadian multicenter, open-label randomized controlled trial assessed the efficacy and safety of remdesivir in hospitalized COVID-19 patients. Conducted as part of the WHO Solidarity trial, 1,282 patients were randomized to receive either remdesivir plus standard care or standard care alone. The study found no statistically significant difference in in-hospital

Read More »
June 26, 2025 No Comments

RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

This 2020 study by Gautret et al. claimed that hydroxychloroquine, particularly when combined with azithromycin, significantly reduced SARS-CoV-2 viral load in COVID-19 patients. The open-label, non-randomized trial involved 36 participants and reported that the combination therapy led to faster viral clearance compared to controls. However, the study faced immediate criticism

Read More »
June 26, 2025 No Comments

COVID-19 Infections in Gonads: Consequences on Fertility?

This 2022 review examines the potential effects of COVID-19 on human reproductive health. It discusses how SARS-CoV-2 may impact gonadal function through ACE2 and TMPRSS2 expression in reproductive tissues, leading to possible tissue inflammation and dysfunction. In women, the pandemic has been associated with menstrual irregularities, reduced oocyte quality, and

Read More »
June 26, 2025 No Comments

Ozone therapy in COVID-19: A narrative review

This 2021 narrative review titled “Ozone therapy in COVID-19: A narrative review” (Virus Research, DOI: [10.1016/j.virusres.2020.198207*) assessed the potential role of ozone therapy as an adjunctive treatment for COVID-19. The authors discussed how ozone’s antiviral, anti-inflammatory, immunomodulatory, and oxygenation-enhancing properties could theoretically target key pathophysiological processes like cytokine storms and

Read More »
June 26, 2025 No Comments

Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach

This 2022 review article published in International Immunopharmacology (DOI: 10.1016/j.intimp.2022.109130) provides a comprehensive overview of Interleukin-6 (IL-6), a key cytokine involved in both immune regulation and immune dysregulation. IL-6 plays a central role in inflammation, B and T cell activity, acute-phase responses, and is pivotal in autoimmune and chronic inflammatory

Read More »
June 26, 2025 No Comments